Bristol Myers Squibb has or is discontinuing?Daklinza?(daclatasvir) in countries where the product is no longer routinely prescribed or?there are other therapeutic options available. Daklinza?played a significant role in providing a new era of treatment, offering patients across the globe the potential for cure from?chronic HCV?infection.??New Hepatitis C treatments have built on the safety and efficacy profile of?Daklinza?to offer shorter treatment durations and a reduced pill burden, and thus providing patients more options for a potential cure.??
Following the lapse / withdrawal of the marketing authorization in each country, the patents in that country will also be allowed to lapse. In the interim period between the lapse / withdrawal of a marketing authorization and patent expiry, Bristol Myers Squibb will not enforce its Daklinza patents in that country.?This policy is specific for?Daklinza?moving forward.?